Answers are grounded in this paper and cite their sources.
Precision medicine aims for clinical remission in severe asthma, highlighting the need for further advancements.
The management of severe asthma has shifted to a precision medicine paradigm based on molecular phenotyping. Biologics have made clinical remission an attainable goal for many patients. Future research must focus on therapies for non-type 2 asthma, refining dynamic biomarkers, and establishing long-term disease-modifying effects.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: